Exscientia (NASDAQ:EXAI) Trading 6.3% Higher

Shares of Exscientia plc (NASDAQ:EXAI) traded up 6.3% during trading on Tuesday . The stock traded as high as $4.62 and last traded at $4.53. 75,480 shares were traded during mid-day trading, a decline of 88% from the average session volume of 613,803 shares. The stock had previously closed at $4.26.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Morgan Stanley restated an “equal weight” rating and issued a $7.00 price target on shares of Exscientia in a research note on Monday, April 22nd. Barclays dropped their target price on shares of Exscientia from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Monday, July 29th. Finally, TD Cowen assumed coverage on shares of Exscientia in a report on Tuesday, July 9th. They issued a “buy” rating for the company.

Exscientia Trading Up 15.0 %

The company has a market cap of $592.35 million, a price-to-earnings ratio of -3.56 and a beta of 0.85. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.05. The firm’s 50-day moving average price is $5.26 and its 200 day moving average price is $5.45.

Exscientia (NASDAQ:EXAI) last issued its quarterly earnings data on Tuesday, May 21st. The company reported ($0.21) earnings per share for the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The company had revenue of $6.70 million for the quarter. As a group, equities analysts expect that Exscientia plc will post -1.12 EPS for the current year.

Hedge Funds Weigh In On Exscientia

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in Exscientia by 108.8% during the second quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after purchasing an additional 202,377 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in Exscientia during the fourth quarter valued at approximately $207,000. New Republic Capital LLC purchased a new stake in shares of Exscientia during the fourth quarter valued at approximately $128,000. Jump Financial LLC boosted its stake in shares of Exscientia by 47.7% during the fourth quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock valued at $345,000 after purchasing an additional 17,355 shares during the period. Finally, Private Advisor Group LLC lifted its stake in Exscientia by 114.3% in the fourth quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $144,000 after acquiring an additional 12,000 shares during the period. 41.58% of the stock is owned by hedge funds and other institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.